(Q43037965)

12 November 2017

title

Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

2

1 reference

12 November 2017

Chi Kong Li

1

1 reference

12 November 2017

Siu Cheung Ling

series ordinal

3

1 reference

12 November 2017

Shau Yin Ha

series ordinal

4

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

British Journal of Haematology

12 November 2017

published in

1 reference

12 November 2017

volume

117

1 reference

12 November 2017

issue

3

1 reference

12 November 2017

page(s)

755-758

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03491.X

Crossref

reference URL

Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03491.X

Crossref

reference URL

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03491.X

Crossref

reference URL

10.1046/J.1365-2141.2002.03491.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference